A5049507490- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Acute Ischemic Stroke Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Intracerebral and Subarachnoid Hemorrhage Research
- Cardiac Imaging and Diagnostics
- Blood Pressure and Hypertension Studies
- Heart Failure Treatment and Management
- Acute Myocardial Infarction Research
- Cardiovascular Function and Risk Factors
- Healthcare cost, quality, practices
- Trauma and Emergency Care Studies
- Heart Rate Variability and Autonomic Control
- Cardiovascular Health and Disease Prevention
- Aortic Disease and Treatment Approaches
- Cardiac Arrest and Resuscitation
- Cardiac Valve Diseases and Treatments
Aalborg University Hospital
2014-2022
Aalborg University
2015-2022
Thrombosis Research Institute
2015
University of Birmingham
2014
Birmingham City Hospital
2014
The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], 65-75 years, sex category [female]) is used clinically for stroke risk stratification in atrial fibrillation (AF). Its usefulness a population of patients with failure (HF) unclear.To investigate whether predicts stroke, thromboembolism, and death cohort...
Substantial interest has been directed towards stroke risk stratification in patients with atrial fibrillation (AF) but prior studies have focused on AF without significant valvular heart disease (VHD), so-called 'non-valvular AF'. A formal validation exercise addressing risks relation to the CHA2DS2-VASc factor(s) VHD is lacking. Also, use of HAS-BLED score anticoagulated not previously studied. The aim this study was investigate and bleeding rates scores. We conducted a nationwide cohort...
The risk of stroke and death in patients with atrial fibrillation is strongly associated age concomitant comorbidities. aim this study was to examine the dependence factors for mortality young fibrillation.This a population-based cohort 30- 65-year-old diagnosed during 2000 2011, identified by record linkage between nationwide Danish registries. Cox regression models were used estimate according within groups: 30 50, 50 65, 65 75 years.We 73,799 nonvalvular patients, which 37,782 (51.2%) <65...
To describe the risks of thromboembolism and major bleeding complications in anticoagulated patients with atrial fibrillation (AF) native aortic or mitral valvular heart disease using data reflecting clinical practice.Descriptive cohort study incident AF disease, identified nationwide Danish registries from 2000 to 2018. A total 10 043 were included, which 5190 (51.7%) had stenosis, 1788 (17.8%) regurgitation, 327 (3.3%) 2738 (27.3%) regurgitation. At 1 year after diagnosis, risk was 4.6%...
The aim of this study was to assess the prognostic value chronic kidney disease (CKD) in relation ischaemic stroke, intracranial haemorrhage, major bleeding, and all-cause death heart failure patients without atrial fibrillation.In observational cohort study, fibrillation were identified using Danish nationwide registries. Risk calculated after 1 5 years compare with CKD, ±dialysis [dialysis: CKD renal replacement therapy (CKD-RRT); no dialysis: CKD-no RRT]. A total 43 199 included, among...
Aims The risks of thromboembolism and bleeding in patients with atrial fibrillation (AF) valvular heart disease (VHD) are sparsely described. We described the risk events non-anticoagulated anticoagulated AF VHD according to evaluated valves, rheumatic or artificial valve classification (EHRA classification), EHRA Type 1 2 VHD, within subgroups VHD. Methods Results Cohort study coexisting identified nationwide Danish registries from 2000 2018. Risk after year follow-up were calculated each...
Background Guideline recommendations on the use of non–vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with aortic stenosis are based studies including a low number stenosis. The aim this study was to estimate effects NOAC versus warfarin thromboembolism and major bleeding among AF Methods Results We emulated target trial using observational data from Danish nationwide registries between 2013 2018. Thromboembolism defined as hospital diagnosis ischemic...
Objectives Critical and chronic illness in youth such as diabetes can lead to impaired mental health. Despite the potentially traumatic life-threatening nature of venous thromboembolism (VTE), long-term health adolescents young adults with VTE is unclear. We compared versus insulin-dependent mellitus (IDDM) using psychotropic drug purchase proxy for Design Nationwide registry-based cohort study. Setting Denmark 1997–2015. Participants All patients aged 13–33 years an incident diagnosis...
In patients with intracerebral hemorrhage (ICH) and prevalent atrial fibrillation (AF), the optimal stroke prevention strategy is unclear. We sought to estimate risk of cerebrovascular events among ICH survivors AF.
Stroke and mortality risk among heart failure patients previously diagnosed with different manifestations of vascular disease is poorly described. We conducted an observational study to evaluate the stroke without atrial fibrillation peripheral artery (PAD) or prior myocardial infarction (MI).Population-based cohort incident during 2000-2012 fibrillation, identified by record linkage between nationwide registries in Denmark. Hazard rate ratios ischemic all-cause death after 1 year follow-up...
This study sought to describe the risk of thromboembolism in nonanticoagulated atrial fibrillation patients with Evaluated Heartvalves, Rheumatic or Artificial (EHRA) Type 2 valvular heart disease (VHD) <65 65 74 years age and 0 1 non-sex comorbidity CHA2DS2-VASc score. A minor, but important, proportion VHD beyond moderate-to-severe mitral stenosis and/or a mechanical prosthetic valve, so-called EHRA VHD, have coexisting comorbidities score, are therefore not strongly recommended oral...
Abstract Background Atrial fibrillation (AF) and valvular heart disease (VHD) often coexist. They are independent causes of mortality morbidity, both have been associated with risk thromboembolic events. Historically, the definition VHD in AF patients has inconsistent, which led to proposal a new classification VHD: “Evaluated Heartvalves, Rheumatic or Artificial” (EHRA) valve classification, categorizing into: EHRA Type 1 2 VHD. comprises mitral stenosis (moderate-severe, rheumatic origin)...
Abstract Background Patients with atrial fibrillation and valvular heart disease (VHD) beyond moderate-to-severe mitral stenosis and/or a mechanical prosthetic valve, so-called EHRA Type 2 VHD, have been associated higher risk of thromboembolism compared patients no VHD. A minor but important proportion VHD has 0 or 1 coexisting CHA2DS2-VASc stroke factors, are therefore not strongly recommended oral anticoagulant therapy according to guidelines. Whether these “truly low” investigated. We...
Abstract Background In patients with atrial fibrillation (AF), who have suffered an intracerebral haemorrhage (ICH), the optimal stroke prevention strategy is unclear. The PRESTIGE-AF trial a multinational randomized controlled designed to investigate in AF recently ICH. Until results of becomes available, data on risk future cerebrovascular events patient surviving ICH are important gain knowledge this group and support clinician challenging situation. Purpose To study population survivors...